Signs and symptoms of COVID-19 in patients with multiple sclerosis.
COVID-19
demyelinating diseases
disease-modifying treatment
multiple sclerosis
neurological disorders
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
31
08
2022
received:
04
04
2022
accepted:
31
08
2022
pubmed:
11
9
2022
medline:
4
11
2022
entrez:
10
9
2022
Statut:
ppublish
Résumé
Clinical outcomes of multiple sclerosis (MS) patients affected by coronavirus disease 2019 (COVID-19) have been thoroughly investigated, but a further analysis on main signs and symptoms and their risk factors still needs attention. The objective of this study was to group together and describe based on similarity the most common signs and symptoms of COVID-19 in MS patients and identify all factors associated with their manifestation. Logistic and linear regression models were run to recognize factors associated with each pooled group of symptoms and their total number. From March 2020 to November 2021, data were collected from 1354 MS patients with confirmed infection of COVID-19. Ageusia and anosmia was less frequent in older people (odds ratio [OR] 0.98; p = 0.005) and more in smoker patients (OR 1.39; p = 0.049). Smoke was also associated with an incremental number of symptoms (OR 1.24; p = 0.031), substance abuse (drugs or alcohol), conjunctivitis and rash (OR 5.20; p = 0.042) and the presence of at least one comorbidity with shortness of breath, tachycardia or chest pain (OR 1.24; p = 0.008). Some disease-modifying therapies were associated with greater frequencies of certain COVID-19 symptoms (association between anti-CD20 therapies and increment in the number of concomitant symptoms: OR 1.29; p = 0.05). Differences in frequencies between the three waves were found for flu-like symptoms (G1, p = 0.024), joint or muscle pain (G2, p = 0.013) and ageusia and anosmia (G5, p < 0.001). All cases should be referred to variants up to Delta. Several factors along with the choice of specific therapeutic approaches might have a different impact on the occurrence of some COVID-19 symptoms.
Sections du résumé
BACKGROUND AND PURPOSE
Clinical outcomes of multiple sclerosis (MS) patients affected by coronavirus disease 2019 (COVID-19) have been thoroughly investigated, but a further analysis on main signs and symptoms and their risk factors still needs attention. The objective of this study was to group together and describe based on similarity the most common signs and symptoms of COVID-19 in MS patients and identify all factors associated with their manifestation.
METHOD
Logistic and linear regression models were run to recognize factors associated with each pooled group of symptoms and their total number.
RESULTS
From March 2020 to November 2021, data were collected from 1354 MS patients with confirmed infection of COVID-19. Ageusia and anosmia was less frequent in older people (odds ratio [OR] 0.98; p = 0.005) and more in smoker patients (OR 1.39; p = 0.049). Smoke was also associated with an incremental number of symptoms (OR 1.24; p = 0.031), substance abuse (drugs or alcohol), conjunctivitis and rash (OR 5.20; p = 0.042) and the presence of at least one comorbidity with shortness of breath, tachycardia or chest pain (OR 1.24; p = 0.008). Some disease-modifying therapies were associated with greater frequencies of certain COVID-19 symptoms (association between anti-CD20 therapies and increment in the number of concomitant symptoms: OR 1.29; p = 0.05). Differences in frequencies between the three waves were found for flu-like symptoms (G1, p = 0.024), joint or muscle pain (G2, p = 0.013) and ageusia and anosmia (G5, p < 0.001). All cases should be referred to variants up to Delta.
CONCLUSION
Several factors along with the choice of specific therapeutic approaches might have a different impact on the occurrence of some COVID-19 symptoms.
Identifiants
pubmed: 36086905
doi: 10.1111/ene.15554
pmc: PMC9538224
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3728-3736Investigateurs
Gianmarco Abbadessa
(G)
Umberto Aguglia
(U)
Lia Allegorico
(L)
Beatrice Maria Rossi Allegri
(BM)
Anastasia Alteno
(A)
Maria Pia Amato
(MP)
Pietro Annovazzi
(P)
Carlo Antozzi
(C)
Lucia Appendino
(L)
Sebastiano Arena
(S)
Viola Baione
(V)
Roberto Balgera
(R)
Valeria Barcella
(V)
Damiano Baroncini
(D)
Caterina Barrilà
(C)
Alessandra Bellacosa
(A)
Gianmarco Bellucci
(G)
Valeria Bergamaschi
(V)
Daiana Bezzini
(D)
Beatrice Biolzi
(B)
Alvino Bisecco
(A)
Simona Bonavita
(S)
Giovanna Borriello
(G)
Chiara Bosa
(C)
Antonio Bosco
(A)
Francesca Bovis
(F)
Marco Bozzali
(M)
Laura Brambilla
(L)
Vincenzo Brescia Morra
(V)
Maria Buccafusca
(M)
Elisabetta Bucciantini
(E)
Sebastiano Bucello
(S)
Maria Chiara Buscarinu
(MC)
Maria Paola Cabboi
(MP)
Massimiliano Calabrese
(M)
Francesca Calabria
(F)
Francesca Caleri
(F)
Federico Camilli
(F)
Luisa Maria Caniatti
(LM)
Roberto Cantello
(R)
Ruggero Capra
(R)
Rocco Capuano
(R)
Patrizia Carta
(P)
Maria Grazia Celani
(MG)
Maria Cellerino
(M)
Raffaella Cerqua
(R)
Clara Chisari
(C)
Raffaella Clerici
(R)
Marinella Clerico
(M)
Gaia Cola
(G)
Antonella Conte
(A)
Marta Zaffira Conti
(MZ)
Christian Cordano
(C)
Susanna Cordera
(S)
Francesco Corea
(F)
Claudio Correale
(C)
Salvatore Cottone
(S)
Francesco Crescenzo
(F)
Erica Curti
(E)
Alessandro d'Ambrosio
(A)
Emanuele D'Amico
(E)
Maura Chiara Danni
(MC)
Alessia d'Arma
(A)
Vincenzo Dattola
(V)
Stefano de Biase
(S)
Giovanna De Luca
(G)
Stefania Federica De Mercanti
(SF)
Paolo De Mitri
(P)
Nicola De Stefano
(N)
Fabio Maria Della Cava
(FM)
Marco Della Cava
(MD)
Sonia Di Lemme
(S)
Mario di Napoli
(M)
Alessia Di Sapio
(A)
Renato Docimo
(R)
Anna Dutto
(A)
Luana Evangelista
(L)
Salvatore Fanara
(S)
Roberta Fantozzi
(R)
Diana Ferraro
(D)
Maria Teresa Ferrò
(MT)
Cristina Fioretti
(C)
Mario Fratta
(M)
Jessica Frau
(J)
Marzia Fronza
(M)
Roberto Furlan
(R)
Alberto Gajofatto
(A)
Antonio Gallo
(A)
Paolo Gallo
(P)
Claudio Gasperini
(C)
Anna Ghazaryan
(A)
Bruno Giometto
(B)
Francesca Gobbin
(F)
Flora Govone
(F)
Franco Granella
(F)
Erica Grange
(E)
Maria Grazia Grasso
(MG)
Luigi M E Grimaldi
(LME)
Angelica Guareschi
(A)
Clara Guaschino
(C)
Simone Guerrieri
(S)
Donata Guidetti
(D)
Ina Barbara Juergenson
(IB)
Pietro Iaffaldano
(P)
Antonio Ianniello
(A)
Luigi Iasevoli
(L)
Daniele Imperiale
(D)
Maria Teresa Infante
(MT)
Rosa Iodice
(R)
Aniello Iovino
(A)
Giovanna Konrad
(G)
Doriana Landi
(D)
Caterina Lapucci
(C)
Luigi Lavorgna
(L)
Maria Rita L'Episcopo
(MR)
Serena Leva
(S)
Giuseppe Liberatore
(G)
Marianna Lo Re
(M)
Marco Longoni
(M)
Leonardo Lopiano
(L)
Lorena Lorefice
(L)
Matteo Lucchini
(M)
Giacomo Lus
(G)
Davide Maimone
(D)
Maria Malentacchi
(M)
Giulia Mallucci
(G)
Simona Malucchi
(S)
Chiara Rosa Mancinelli
(CR)
Luca Mancinelli
(L)
Paolo Manganotti
(P)
Giorgia Teresa Maniscalco
(GT)
Vittorio Mantero
(V)
Sabrina Marangoni
(S)
Damiano Marastoni
(D)
Fabiana Marinelli
(F)
Alessandro Marti
(A)
Filippo Boneschi Martinelli
(F)
Zoli Federco Masserano
(ZF)
Francesca Matta
(F)
Laura Mendozzi
(L)
Giuseppe Meucci
(G)
Silvia Miante
(S)
Giuseppina Miele
(G)
Eva Milano
(E)
Massimiliano Mirabella
(M)
Rosanna Missione
(R)
Marcello Moccia
(M)
Lucia Moiola
(L)
Sara Montepietra
(S)
Margherita MontiBragadin
(M)
Federico Montini
(F)
Roberta Motta
(R)
Raffaele Nardone
(R)
Carolina Gabri Nicoletti
(C)
Eduardo Nobile-Orazio
(E)
Agostino Nozzolillo
(A)
Marco Onofrj
(M)
Riccardo Orlandi
(R)
Anna Palmieri
(A)
Damiano Paolicelli
(D)
Livia Pasquali
(L)
Luisa Pastò
(L)
Elisabetta Pedrazzoli
(E)
Maria Petracca
(M)
Alfredo Petrone
(A)
Carlo Piantadosi
(C)
Anna M Pietroboni
(AM)
Federica Pinardi
(F)
Emilio Portaccio
(E)
Mattia Pozzato
(M)
Carlo Pozzilli
(C)
Luca Prosperini
(L)
Alessandra Protti
(A)
Paolo Ragonese
(P)
Sarah Rasia
(S)
Sabrina Realmuto
(S)
Anna Repice
(A)
Eleonora Rigoni
(E)
Maria Teresa Rilla
(MT)
Francesca Rinaldi
(F)
Calogero Marcello Romano
(CM)
Marco Ronzoni
(M)
Marco Rovaris
(M)
Francesca Ruscica
(F)
Loredana Sabattini
(L)
Giuseppe Salemi
(G)
Lorenzo Saraceno
(L)
Alessia Sartori
(A)
Arianna Sartori
(A)
Elvira Sbragia
(E)
Giuditta Ilaria Scarano
(GI)
Valentina Scarano
(V)
Maria Sessa
(M)
Caterina Sgarito
(C)
Grazia Sibilia
(G)
Gabriele Siciliano
(G)
Alessio Signori
(A)
Elisabetta Signoriello
(E)
Leonardo Sinisi
(L)
Francesca Sireci
(F)
Patrizia Sola
(P)
Claudio Solaro
(C)
Stefano Sotgiu
(S)
Maddalena Sparaco
(M)
Maria Laura Stromillo
(ML)
Silvia Strumia
(S)
Emanuela Laura Susani
(EL)
Giulietta Tabiadon
(G)
Francesco Teatini
(F)
Valentina Tomassini
(V)
Simone Tonietti
(S)
Valentina Torri
(V)
Carla Tortorella
(C)
Simona Toscano
(S)
Rocco Totaro
(R)
Maria Trotta
(M)
Gabriella Turano
(G)
Monica Ulivelli
(M)
Manzo Valentino
(M)
Giovanna Vaula
(G)
Domizia Vecchio
(D)
Marco Vercellino
(M)
Elena Pinuccia Verrengia
(EP)
Marika Vianello
(M)
Eleonora Virgilio
(E)
Francesca Vitetta
(F)
Stefano Vollaro
(S)
Mauro Zaffaroni
(M)
Mauro Zampolini
(M)
Ignazio Roberto Zarbo
(IR)
Antonio Zito
(A)
Luigi Zuliani
(L)
Informations de copyright
© 2022 European Academy of Neurology.
Références
Vena A, Giacobbe DR, Di Biagio A, et al. Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy. Clin Microbiol Infect. 2020;26(11):1537-1544. doi:10.1016/j.cmi.2020.07.049
Centers for Disease Control and Prevention. Symptoms of COVID-19. Centers for Disease Control and Prevention; 2021.
Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). StatPearls. StatPearls Publishing; 2021.
Pettrone K, Burnett E, Link-Gelles R, et al. Characteristics and risk factors of hospitalized and nonhospitalized COVID-19 patients, Atlanta, Georgia, USA, March-April 2020. Emerg Infect Dis. 2021;27(4):1164-1168. doi:10.3201/eid2704.204709
Najafloo R, Majidi J, Asghari A, et al. Mechanism of anosmia caused by symptoms of COVID-19 and emerging treatments. ACS Chem Nerosci. 2021;12(20):3795-3805. doi:10.1021/acschemneuro.1c00477
Struyf T, Deeks JJ, Dinnes J, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst Rev. 2020;7(7):CD013665. doi:10.1002/14651858.CD013665
Elliott J, Whitaker M, Bodinier B, et al. Predictive symptoms for COVID-19 in the community: REACT-1 study of over 1 million people. PLoS Med. 2021;18(9):e1003777. doi:10.1371/journal.pmed.1003777
Barometro della Sclerosi Multipla 2021. © AISM. ISBN 978-88-7148-152-4
Winkelmann A, Loebermann M, Reisinger EC, Hartung HP, Zettl UK. Disease modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol. 2016;12:217-233.
Sormani MP, De Rossi N, Schiavetti I, et al. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol. 2021;89(4):780-789. doi:10.1002/ana.26028
Louapre C, Collongues N, Stankoff B, et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol. 2020;77(9):1079-1088. doi:10.1001/jamaneurol.2020.2581
Fragoso YD, Schiavetti I, Carmisciano L, et al. Coronavirus disease 2019 in Latin American patients with multiple sclerosis. Mult Scler Relat Disord. 2021;55:103173. doi:10.1016/j.msard.2021.103173
Landtblom AM, Berntsson SG, Boström I, Iacobaeus E. Multiple sclerosis and COVID-19: the Swedish experience. Acta Neurol Scand. 2021;144(3):229-235. doi:10.1111/ane.13453
Sen S, Karabudak R, Schiavetti I, et al. The outcome of a national MS-COVID-19 study: what the Turkish MS cohort reveals? Mult Scler Relat Disord. 2021;52:102968. doi:10.1016/j.msard.2021.102968
Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615. doi:10.1038/s41591-021-01283-z
Kratzer B, Trapin D, Ettel P, et al. Immunological imprint of COVID-19 on human peripheral blood leukocyte populations. Allergy. 2021;76:751-765. doi:10.1111/all.14647
Barzegar M, Mirmosayyeb O, Gajarzadeh M, et al. COVID-19 among patients with multiple sclerosis: a systematic review. Neurol Neuroimmunol Neuroinflamm. 2021;8(4):e1001. doi:10.1212/NXI.0000000000001001 [published correction appears in Neurol Neuroimmunol Neuroinflamm. 2021;8(5):e1050].
Sierpiński R, Pinkas J, Jankowski M, et al. Sex differences in the frequency of gastrointestinal symptoms and olfactory or taste disorders in 1942 nonhospitalized patients with coronavirus disease 2019 (COVID-19). Pol Arch Intern Med. 2020;130:501-505. doi:10.20452/pamw.15414
Sehanobish E, Barbi M, Fong V, et al. COVID-19-induced anosmia and ageusia are associated with younger age and lower blood eosinophil counts. Am J Rhinol Allergy. 2021;35(6):830-839. doi:10.1177/19458924211004800
Wehling E, Nordin S, Espeseth T, Reinvang I, Lundervold AJ. Unawareness of olfactory dysfunction and its association with cognitive functioning in middle aged and old adults. Arch Clin Neuropsychol. 2011;26(3):260-269. doi:10.1093/arclin/acr019
Study ZOE COVID. Is shortness of breath a symptom of COVID-19?. Accessed April 1, 2021. https://covid.joinzoe.com/post/covid-symptoms-shortness-breath
Jain NP, Shao K, Stewart C, Grant-Kels JM. The effects of alcohol and illicit drug use on the skin. Clin Dermatol. 2021;39(5):772-783. doi:10.1016/j.clindermatol.2021.05.005
Gohil H, Miskovic M, Buxton JA, Holland SP, Strike C. Smoke gets in the eye: a systematic review of case reports of ocular complications of crack cocaine use. Drug Alcohol Rev. 2021;41(2):347-355. doi:10.1111/dar.13366
Katotomichelakis M, Balatsouras D, Tripsianis G, et al. The effect of smoking on the olfactory function. Rhinology. 2007;45(4):273-280.
Lippi G, Henry BM. Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). Eur J Intern Med. 2020;75:107-108. doi:10.1016/j.ejim.2020.03.014
Farsalinos K, Barbouni A, Poulas K, Polosa R, Caponnetto P, Niaura R. Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis. Ther Adv Chronic Dis. 2020;11:204062232093576. doi:10.1177/2040622320935765
van Westen-Lagerweij NA, Meijer E, Meeuwsen EG, et al. Are smokers protected against SARS-CoV-2 infection (COVID-19)? The origins of the myth. NPJ Prim Care Respir Med. 2021;31:10. doi:10.1038/s41533-021-00223-1
Zhao Q, Meng M, Kumar R, et al. The impact of COPD and smoking history on the severity of COVID-19: a systemic review and meta-analysis. J Med Virol. 2020;92:1915-1921.
Fernández Ó, Giovannoni G, Fox RJ, et al. Efficacy and safety of delayed-release dimethyl fumarate for relapsing-remitting multiple sclerosis in prior interferon users: an integrated analysis of DEFINE and CONFIRM. Clin Ther. 2017;39(8):1671-1679. doi:10.1016/j.clinthera.2017.06.012
Equils O, Lekaj K, Wu A, Fattani S, Liu G, Rink L. Intra-nasal zinc level relationship to COVID-19 anosmia and type 1 interferon response: a proposal. Laryngoscope Investig Otolaryngol. 2020;6(1):21-24. doi:10.1002/lio2.513
Mayet AY. Loss of smell (anosmia) and taste (ageusia) in a patient treated with pegylated interferon alfa and ribavirin. Curr Ther Res Clin Exp. 2007;68(4):271-277. doi:10.1016/j.curtheres.2007.08.006
Kraus I, Vitezic D. Anosmia induced with alpha interferon in a patient with chronic hepatitis C. Int J Clin Pharmacol Ther. 2000;38(7):360-361. doi:10.5414/cpp38360
Maruyama S, Hirayama C, Kadowaki Y, Sagayama A, Omura H, Nakamoto M. Interferon-induced anosmia in a patient with chronic hepatitis C. Am J Gastroenterol. 1998;93:122-123.
Taboada M, González M, Alvarez A, et al. First, second and third wave of COVID-19. What have we changed in the ICU management of these patients? J Infect. 2021;82(6):e14-e15. doi:10.1016/j.jinf.2021.03.027
Borghesi A, Golemi S, Carapella N, Zigliani A, Farina D, Maroldi R. Lombardy, northern Italy: COVID-19 second wave less severe and deadly than the first? A preliminary investigation. Infect Dis (Lond). 2021;53(5):370-375. doi:10.1080/23744235.2021.1884745
Jung C, Excoffier JB, Raphaël-Rousseau M, Salaün-Penquer N, Ortala M, Chouaid C. Evolution of hospitalized patient characteristics through the first three COVID-19 waves in Paris area using machine learning analysis. PLoS One. 2022;17(2):e0263266. doi:10.1371/journal.pone.0263266
Hodcroft EB, Zuber M, Nadeau S, et al. Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. Nature. 2021;595(7869):707-712. doi:10.1038/s41586-021-03677-y
Lam S, Lombardi A, Ouanounou A. COVID-19: a review of the proposed pharmacological treatments. Eur J Pharmacol. 2020;886:173451. doi:10.1016/j.ejphar.2020.173451